Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: A cost-effectiveness analysis

American Journal of Transplantation

Volumn 13, Issue 10, 2013, Pages 2611-2618

  Lai, J C ^a   Kahn, J G ^a   Tavakol, M ^a   Peters, M G ^a   Roberts, J P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness analysis; graft; organ transplantation; surgery

Indexed keywords

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION CONTROL; MALE; MEDICAL DECISION MAKING; NUCLEIC ACID AMPLIFICATION; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

COST-EFFECTIVENESS ANALYSIS; GRAFT; ORGAN TRANSPLANTATION; SURGERY;

BLOOD DONORS; COST-BENEFIT ANALYSIS; DECISION MAKING; DNA, VIRAL; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MASS SCREENING; MODELS, ECONOMIC; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ORGAN TRANSPLANTATION; PROGNOSIS;

EID: 84884906244     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12429     Document Type: Article

References (43)

1. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929-1935.
2. CDC. CDC Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Morb Mortal Wkly Rep 1994; 43: 1-26.
3. Yao F, Seed C, Farrugia A, et al. The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. Am J Transplant 2007; 7: 2723-2726.
4. Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003; 43: 788-798.
5. Busch MP, Glynn SA, Wright DJ, et al. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005; 45: 1853-1863.
6. Giachetti C, Linnen JM, Kolk DP, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002; 40: 2408-2419.
7. Seem DL, Lee I, Umscheid CA, Kuehnert MJ., PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013; 128: 247-392.
8. Kucirka LM, Alexander C, Namuyinga R, Hanrahan C, Montgomery RA, Segev DL., Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009; 9: 620-628.
9. Ellingson K, Seem D, Nowicki M, Strong DM, Kuehnert MJ, for the Organ Procurement Organization Nucleic Acid Testing Yield Project Team. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011; 11: 1201-1208.
10. Kontodimopoulos N, Niakas D., An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 2008; 86: 85-96.
11. Åberg F, Mäklin S, Räsänen P, et al. Cost of a quality-adjusted life year in liver transplantation: The influence of the indication and the model for end-stage liver disease score. Liver Transpl 2011; 17: 1333-1343.
12. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420.
13. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-726.
14. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ., Liver transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-1019.
15. Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health 2008; 11: 1144-1153.
16. Scott DR, Wong JKW, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-1171.
17. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-638.
18. Sherman KE, Sherman SN, Chenier T, Tsevat J., Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164: 2377-2382.
19. Malinoski DJ, Patel MS, Daly MC, Oley-Graybill C, Salim A., The impact of meeting donor management goals on the number of organs transplanted per donor. Crit Care Med 2012; 40: 2773-2780.
20. Mendeloff J, Ko K, Roberts MS, Byrne M, Dew MA., Procuring organ donors as a health investment: How much should we be willing to spend ? Transplantation 2004; 78: 1704-1710.
21. Machnicki G, Seriai L, Schnitzler MA., Economics of transplantation: A review of the literature. Transplant Rev 2006; 20: 61-75.
22. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis-C infection in high infectious risk donors: Systematic review and meta-analysis. Am J Transplant 2011; 11: 1188-1200.
23. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG., Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20: 332-342.
24. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86: 28-40.
25. Jackson BR, Busch MP, Stramer SL, AuBuchon JP., The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43: 721-729.
26. Davidson T, Ekermo B, Gaines H, Lesko B, Åkerlind B., The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. Transfusion 2010; 51: 421-429.
27. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high infectious risk donors: Systematic review and meta-analysis. Am J Transplant 2011; 11: 1176-1187.
28. HIV Organ Policy Equity Act. thomas.loc.gov. Available at: http://thomas.loc.gov/cgi-bin/query/z?c113:H.R.698. Accessed January 31, 2013.
29. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: Is the "Best" test the right test? A consensus conference report. Am J Transplant 2010; 10: 889-899.
30. Summary of basis for approval-NGI UltraQual™ HIV-1 RT-PCR assay. Food and Drug Administration, 1-8. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ BloodDonorScreening/InfectiousDisease/UCM093942.pdf. Accessed January 31, 2013.
31. Summary of basis for approval-Procleix® Ultrio® Assay for HIV-1, HCV RNA, and HBV DNA. Food and Drug Administration, 2004; 1-68. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ UCM244479.pdf. Accessed January 31, 2013.
32. Summary of basis for approval-HIQ-PCR™ HIV-1 RT-PCR assay. Food and Drug Administration, 1-6. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ BloodDonorScreening/InfectiousDisease/ucm093987.pdf. Accessed January 31, 2013.
33. Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990; 113: 733-739.
34. Berglund O, Beckman S, Grillner L, et al. HIV transmission by blood transfusions in Stockholm 1979-1985: Nearly uniform transmission from infected donors. AIDS 1988; 2: 51-54.
35. Landin L, Rodriguez-Perez JC, Garcia-Bello MA, et al. Kidney transplants in HIV-positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephrol Dial Transplant 2010; 25: 3106-3115.
36. Norman SP, Kommareddi M, Kaul DR., Update on kidney transplantation in HIV-infected recipients. AIDS Rev 2012; 14: 195-207.
37. Tengs TO, Lin TH., A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002; 22: 475-481.
38. Owusu-Edusei K Jr., Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40: 197-201.
39. Summary of basis for approval-COBAS® Ampliscreen HCV test. Food and Drug Administration, 1-18. Available at: http://www.fda.gov/downloads/ BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/ BloodDonorScreening/InfectiousDisease/UCM173206.pdf. Accessed January 31, 2013.
40. National hepatitis C prevention strategy. Centers for Disease Control and Prevention, 2001; 1-21. Available at: http://stacks.cdc.gov/view/cdc/6458/. Accessed January 31, 2013.
41. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29: 1220-1226.
42. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836.
43. Razavi H, ElKhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-2170.